{"filing":{"accession_number":"0001140361-26-040177","cik":"0001104506","ticker":"INSM","company_name":"INSMED Inc","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-16","primary_document":"ef20084030_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126040177/ef20084030_8k.htm"},"events":[{"id":36254,"run_id":33417,"accession_number":"0001140361-26-040177","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Insmed appointed two new independent directors effective October 19, 2026: Paul Hudson (former CEO of Sanofi and Novartis) and Utpal Koppikar (CFO of Verily Health). Both received committee assignments and equity compensation packages of approximately $585,000 in RSUs each, bringing significant executive experience to the board at a pivotal time for the company.","company_name":"INSMED Inc","ticker":"INSM","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40603,"accession_number":"0001140361-26-040177","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new independent directors, Paul Hudson (former CEO of Sanofi and Novartis) and Utpal Koppikar (CFO of Verily Health), effective October 19, 2026. Both appointments include committee assignments (Hudson to Compensation Committee, Koppikar to Audit Committee) and equity compensation packages (~$585,000 in RSUs each). This is a material governance event involving the addition of highly experienced executives to the board at a pivotal time for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T11:02:13.358587+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40604,"accession_number":"0001140361-26-040177","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new independent directors to Insmed's Board: Paul Hudson (former CEO of Sanofi and Novartis Pharmaceuticals) and Utpal Koppikar (CFO of Verily Health). The press release emphasizes their significant executive experience and the strategic value they bring to the board at a \"pivotal time\" for the company. This is a clear executive appointment event, material to investors assessing board composition and governance strength.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T11:02:13.358587+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40603,"accession_number":"0001140361-26-040177","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new independent directors, Paul Hudson (former CEO of Sanofi and Novartis) and Utpal Koppikar (CFO of Verily Health), effective October 19, 2026. Both appointments include committee assignments (Hudson to Compensation Committee, Koppikar to Audit Committee) and equity compensation packages (~$585,000 in RSUs each). This is a material governance event involving the addition of highly experienced executives to the board at a pivotal time for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T11:02:13.358587+00:00","company_name":"INSMED Inc","ticker":"INSM","filing_date":"2026-10-20"},{"id":40604,"accession_number":"0001140361-26-040177","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new independent directors to Insmed's Board: Paul Hudson (former CEO of Sanofi and Novartis Pharmaceuticals) and Utpal Koppikar (CFO of Verily Health). The press release emphasizes their significant executive experience and the strategic value they bring to the board at a \"pivotal time\" for the company. This is a clear executive appointment event, material to investors assessing board composition and governance strength.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T11:02:13.358587+00:00","company_name":"INSMED Inc","ticker":"INSM","filing_date":"2026-10-20"}]}